These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
994 related articles for article (PubMed ID: 18640575)
1. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575 [TBL] [Abstract][Full Text] [Related]
2. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583 [TBL] [Abstract][Full Text] [Related]
3. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
4. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755 [TBL] [Abstract][Full Text] [Related]
6. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633 [TBL] [Abstract][Full Text] [Related]
7. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation]. Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931 [TBL] [Abstract][Full Text] [Related]
9. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Remberger M; Svahn BM; Mattsson J; Ringdén O Transplantation; 2004 Jul; 78(1):122-7. PubMed ID: 15257050 [TBL] [Abstract][Full Text] [Related]
10. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G; Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
12. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970 [TBL] [Abstract][Full Text] [Related]
13. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700 [TBL] [Abstract][Full Text] [Related]
15. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Weber M; Kröger N; Langer F; Hansen A; Zabelina T; Eifrig B; Hossfeld DK; Zander AR Bone Marrow Transplant; 2003 May; 31(9):817-22. PubMed ID: 12732891 [TBL] [Abstract][Full Text] [Related]
16. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors. Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038 [TBL] [Abstract][Full Text] [Related]
17. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Kusumi E; Kami M; Yuji K; Hamaki T; Murashige N; Hori A; Kojima R; Kishi Y; Kim SW; Ueyama J; Miyakoshi S; Tanosaki R; Morinaga S; Mori S; Heike Y; Muto Y; Masuo S; Taniguchi S; Takaue Y Bone Marrow Transplant; 2004 Apr; 33(7):697-702. PubMed ID: 14755317 [TBL] [Abstract][Full Text] [Related]
18. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study. Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G; Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759 [TBL] [Abstract][Full Text] [Related]
19. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Remberger M; Svahn BM; Hentschke P; Löfgren C; Ringdén O Bone Marrow Transplant; 1999 Oct; 24(8):823-30. PubMed ID: 10516691 [TBL] [Abstract][Full Text] [Related]
20. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG]. Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]